Podcasts about cll

Drs. Ghia and Scarfò discuss how CAR T-cell therapy is emerging as a powerful option for high-risk CLL and Richter transformation, especially in patients who have failed BTK and BCL-2 inhibitors. They stress that achieving deep remissions, choosing the right patients, and referring early to specialized centers are critical to improving outcomes.

"Measurable residual disease is where I think the terminology fits best in that, it is intended to measure the amount of cancer cells that are present in the blood or bone marrow at the time the sample was collected. We can identify one cancer cell in a million. Where that can be really valuable is when we start to think about the duration of treatments and the response to some of our treatments," ONS member Caitilin Murphy, DNP, APRN, FNP-BC, AOCNP®, chief nurse practitioner at Dana-Farber Cancer Institute in Boston, MA, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about chronic lymphocytic leukemia (CLL) treatment considerations for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD), including 45 minutes of pharmacotherapeutic content, by listening to the full recording and completing an evaluation at courses.ons.org by August 14, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to treatment of chronic lymphocytic leukemia. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 422: An Overview of Chronic Lymphocytic Leukemia for Oncology Nurses Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis Episode 184: Oncologic Emergencies 101: Tumor Lysis Syndrome ONS Voice articles: Fixed-Duration Therapy for CLL May Lower Cardiovascular Risks and Costs Less Than Continuous Treatment Individuals With CLL Face Increased Risk for Skin Cancer Master Hypersensitivity Reactions With These Strategies for Prevention and Management Patients With CLL Report Worse QoL and Other Factors Clinical Journal of Oncology Nursing articles:  Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Pseudohyperkalemia in Chronic Lymphocytic Leukemia: An Often Overlooked Clinical Entity Richter Transformation Arising From Chronic Lymphocytic Leukemia Venetoclax: Management and Care for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia ONS book: Site-Specific Cancer Series: Leukemia (first edition) ONS symptom management resources:  Fatigue Prevention of Bleeding Prevention of Infection: General Blood Cancer United: Chronic Lymphocytic Leukemia Treatment CLL Society: Patient Education Toolkit Lymphoma Research Foundation: Lymphoma Treatments Patient education sheets Acalabrutinib Ibrutinib Pirtobrutinib To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Blood work is a really nice way to evaluate if there is progression of the disease. And we evaluate their blood counts, specifically that complete blood count with a differential. We anticipate an elevated white count, and we anticipate that the absolute lymphocyte count is going to be elevated. That's characteristic of the disease. But what evolves and happens is that those numbers can rapidly change and what we get concerned about is if that white count—and the percentage of the absolute lymphocyte count specifically—starts to increase and double quickly." TS 5:52 "There are some components that help clinicians decide if we expect these things, this cadence of change to happen more readily, or if we feel really comfortable that the biology of the variants contributing to the type of CLL that each patient may have, they may not have that progression as quickly or at all. And so that kind of helps us in that follow-up and cadence. Oftentimes, we're checking blood work every three or six months. Some patients are on an annual interval of visits depending on that active surveillance. I think the other piece is that we have a relatively low threshold when there is a change in symptoms to just recheck those blood tests. It's nice that we can have a pretty readily available blood test to be able to give us a lot of information for these patients." TS 9:45 "When we think about CLL therapy, the old tried and true [treatments] still work: so, rituximab and obinutuzumab. And then we kind of start to think about pathways and the way, the mechanisms of which these treatments are integrated. We think about different pathways of how we can induce cell death, but also what are the potential side effects? What are the potential interactions?" TS 19:35 "I think a lot of this is about really having a clear understanding of the patient's goals and really being able to understand and align. I think we have a lot more data to provide guidance for those patients that really are wanting to know: What is my chance of overall survival? If I do this, does this mean that I don't need to ever be on treatment again? If I do it this way, does it mean that I have to come into clinic every week, or does it mean that I have to come in every week but I'm done? I do one year of treatment, and I don't have to think about treatment for a really long time based on some of these components that we can take into consideration." TS 24:36 "When we think about the B-cell lymphoma 2 (BCL-2) inhibitors, with venetoclax, I think the biggest component we think about is tumor lysis syndrome. It's so effective that these cancer cells release all of those electrolytes, potassium, phosphorus; you can see a rise in the lactate dehydrogenase and uric acid because those cells are breaking down. And so subsequently, that leads us to the consideration of, is the patient's kidney function able to clear it? And so a lot of frequent lab monitoring, a lot of hydration, supportive care with medications like ursodiol or allopurinol to really improve the ability to clear that cellular waste product so that it doesn't cause an oncologic emergency." TS 34:11

In today's episode, we spoke with John N. Allan, MD. Dr Allan is an associate attending physician at New York-Presbyterian Hospital and an associate professor of clinical medicine at Weill Cornell Medical College in New York, New York. In our exclusive interview, Dr Allan discussed his review of the currently approved fixed-duration regimens for chronic lymphocytic leukemia (CLL). Regimens like venetoclax (Venclexta) plus obinutuzumab (Gazyva), ibrutinib (Imbruvica) plus venetoclax, acalabrutinib (Calquence) plus venetoclax, and venetoclax plus rituximab (Rituxan) were all regimens that Allan comparatively delved into. Additionally, Allan discussed insight provided by the review that clinical trials lack, remaining gaps of unmet needs for fixed-duration regimens in CLL, and what research is necessary for the field to conduct moving forward. 

Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics: Case: A man in his mid 40s with chronic lymphocytic leukemia (CLL) receives acalabrutinib/venetoclax as part of the MAJIC trial (0:00) Case: A man in his early 70s with TP53-mutated CLL expresses concern about side effects associated with zanubrutinib (8:22) Case: A man in his late 70s with Stage IIIB chronic kidney disease and CLL receives obinutuzumab (18:02) CME information and select publications

Featuring perspectives from Dr Mazyar Shadman, including the following topics: The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00) The AMPLIFY trial: Fixed-duration acalabrutinib combinations for untreated CLL (5:31) Zanubrutinib-based therapy for treatment-naïve CLL (12:32) CME information and select publications

BloodCancerTalks: ASCO/EHA 2026 Lymphoma Round-Up with Dr. Thomas LewGuest: Dr. Thomas Lew, Peter MacCallum Cancer Centre (Melbourne, Australia) — hematologist specializing in lymphoid malignancies.In this episode, we break down the biggest lymphoma and CLL data from ASCO and EHA 2026 (Chicago and Stockholm), covering mantle cell lymphoma genomics, bispecific antibodies in DLBCL and follicular lymphoma, a practice-changing (or not) CNS prophylaxis study, transplant-eligible relapsed DLBCL, fixed-duration BTK/BCL2 combinations in CLL, and the first in vivo CAR T data in lymphoma.1. TRIANGLE: TP53-Mutated MCL Molecular Subgroup AnalysisMolecular subgroup data from the practice-shaping TRIANGLE trial presented by Dr. Marta Grau.Discussion: Where TP53-mutated MCL stands today, and whether ibrutinib-containing regimens are changing the natural history of this historically dismal subgroup.2. EPCORE DLBCL-1: Epcoritamab vs. Chemotherapy in R/R DLBCLRandomized phase 3 trial (n=483) of bispecific antibody epcoritamab vs. investigator's choice chemotherapy (72% R-GemOx, 28% BR) in second-line-or-later, transplant-ineligible R/R DLBCL, presented by Prof. Chris Fox.Discussion: A PFS benefit without an OS signal, set against a meaningfully higher infection-related mortality — what this means for patient selection and infection mitigation strategies.3. CNS Prophylaxis in Ultra-High-Risk DLBCL: Does HD-MTX Help?Pooled analysis of two large multicenter retrospective cohorts (n=1,923 ultra-high-risk patients — CNS-IPI 5–6, testicular/renal/adrenal/breast involvement, or ≥3 extranodal sites), presented by Dr. Matt Wilson (Glasgow) and simultaneously published in JCO. Discussion: Whether these data close the door on routine HD-MTX in ultra-high-risk DLBCL, and if any subgroup still warrants prophylaxis.4. Pola-R-ICE: A Negative Trial in Transplant-Eligible R/R DLBCLRandomized phase 3 study (4 European cooperative groups; n=294) of polatuzumab vedotin added to R-ICE in transplant-eligible R/R DLBCL, with ASCT/alloSCT/CAR-T permitted as consolidation.Discussion: Why this trial missed, and what it tells us about the ceiling of intensive salvage chemo-immunotherapy platforms in the CAR-T era.5. BRUIN-CLL-322: Fixed-Duration Pirtobrutinib + Venetoclax-Rituximab in R/R CLLRandomized phase 3 trial (n=639) of fixed-duration pirtobrutinib (non-covalent BTKi) plus venetoclax-rituximab (PVR) vs. venetoclax-rituximab (VR, the MURANO-based control) in second-line-or-later R/R CLL.6. SOUNDTRACK-F1: Surovatamig (CD19 Bispecific) Safety Run-In in Untreated Follicular LymphomaSafety run-in from a randomized trial (surovatamig vs. chemoimmunotherapy) in untreated FL meeting GELF criteria, presented by Prof. Chan Cheah — building on EPCORE-FL-1 data presented at ASH.Discussion: How this CD19-directed bispecific compares to CD20-targeting agents in frontline FL.7. LB2501: First In Vivo CAR T Data in B-Cell LymphomaLate-breaking data from Dr. Lei Fan and Legend Biotech on LB2501, an in vivo CD19/CD20 dual-targeted CAR T therapy — a third-generation, self-inactivating, replication-incompetent lentiviral vector that generates CAR T cells directly in vivo, without lymphodepletion. Builds on the in vivo CAR T myeloma data first presented at ASH and updated at EHA.Discussion: What these very early but striking data suggest about the feasibility of in vivo CAR T generation in lymphoma, and how it might reshape access to cellular therapy.BloodCancerTalks is co-hosted by Rajshekhar Chakraborty,  Ashwin Kishtagari and Eddie Cliff. Subscribe wherever you get your podcasts. 

Drs. Chang and Cohen discuss how MRD has become an important tool for assessing how well patients with CLL respond to treatment, beyond what standard blood tests can show. They conclude that although MRD is very useful in research and can help inform conversations with patients, it is not yet clear how or whether it should routinely guide real-world treatment decisions.

Integrate patient perspectives to refine evidence-based therapy for CLL. Credit available for this activity expires: 7/21/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/elevating-cll-care-integrating-evidence-guidelines-and-2026a1000nxr?ecd=bdc_podcast_libsyn_mscpedu

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics: Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00) Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49) Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48) Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43) Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43) Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15) Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30) CME information and select publications

"What I appreciate about our patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia is the consideration that they receive a cancer diagnosis, and the best thing for them to do is actually nothing. There is a large population of patients that we don't recommend any type of treatment. We recommend that they establish care with an oncologist and that they have a relationship with those care teams," ONS member Caitilin Murphy, DNP, APRN, FNP-BC, AOCNP®, chief nurse practitioner at Dana-Farber Cancer Institute in Boston, MA, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about an overview of CLL for oncology nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by July 3, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report increased knowledge of the diagnosis and management of chronic lymphocytic leukemia. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 339: A Lesson on Labs: How to Monitor and Educate Patients With Cancer Episode 256: Cancer Symptom Management Basics: Hematologic Complications ONS Voice articles: Compensation Funds Curb Financial Burden for Certain Exposure-Related Cancers Infection Prevention for Oncology Nurses Nurse-Led Bone Marrow Biopsy Clinics Truncate Time for Testing, Treatment Patient Stress Linked to More Advanced Leukemia Patients With CLL Report Worse QoL and Other Factors Clinical Journal of Oncology Nursing articles:  Care Coordination: Overcoming Barriers to Improve Outcomes for Patients With Hematologic Malignancies in Rural Settings Pseudohyperkalemia in Chronic Lymphocytic Leukemia: An Often Overlooked Clinical Entity Richter Transformation Arising From Chronic Lymphocytic Leukemia ONS book: Site-Specific Cancer Series: Leukemia (first edition) Hematology, Cellular Therapy and Stem Cell Transplantation Learning Library ONS Biomarker Database ONS clinical practice resource: Genomics Taxonomy Blood Cancer United: Chronic Lymphocytic Leukemia: In Detail CLL Society: Patient Education Toolkit Lymphoma Research Foundation: Lymphoma and CLL Publications National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Some of the common risk factors are environmental exposures, occupational exposures, and chemical exposures. For example, in certain farming communities where there are pesticides, that can definitely contribute to the risk of developing CLL. There's some consideration for high levels of radon exposure or exposure to Agent Orange. So our veterans, both from the Vietnam War but also more recently in Iraq. There's definitely a consideration that those types of exposures increase the risk of developing CLL." TS 3:01 "Generally, the average age of diagnosis for CLL is in the seventh decade of life. But over 90% of people are diagnosed at age 50 and above. So, this tends to be a diagnosis in the six or seventh decade of life. It's extremely rare in children, although it has been observed, and it's twice as likely to develop in men than it is compared to women. And then individuals who are White are more frequently affected by CLL than other racial or ethnic groups, followed by people of color. And that includes Black, Hispanic, and Native American individuals, but it's rarer in Asian populations." TS 9:33  "There's a lot of adjustment and coping with a new diagnosis. When we think about the diagnostic approach, we get a lot of information that's incredibly valuable and helps us really to pivot and guide patients as to where they need to go and how we can best support them. We've had well-established studies that look to say, 'If we were to treat patients earlier or have different thresholds for consideration for treatment, do patients do better?' ... I think it's really great that we can actually guide patients in a much more precise way, that you don't need any type of therapy at this point, and it may change and evolve in the future." TS 20:29 "I have some patients that are doers and they want to do something, so this active surveillance or watch and wait really paralyzes their coping. And so they want to do something. Oftentimes, that's really when I pull in some integrative strategies and say exercise is always going to be beneficial. The more active you are, the more physically fit you are. If you really want to do something, make sure that you stay hydrated, that you eat well, and you're engaged in a physical activity that you enjoy and can be consistent with." TS 32:37 "I think another piece that we don't often discuss is around the immunoglobulins and the immune system, but CLL has a pretty significant impact on immune dysfunction. And so patients with CLL, even if they are not on any type of active treatment, their immune system doesn't necessarily function fully. And so they're more likely to develop some upper respiratory infections or more easily develop the flu or coronavirus. ... Often times, we think a lot about supporting patients to get vaccines and to have early evaluation if those symptoms develop because you're more likely to develop upper respiratory infections. I think there's a component around immune dysfunction that I think is really valuable for people to understand that it's not contingent upon the treatment. It's contingent upon the disease and mechanistically, how the B cells are dysfunctional and don't provide that immunity that otherwise would be in a healthy B cell." TS 42:54

Drs. Cohen and Chang review how CLL and its treatments weaken the immune system and lead to poorer responses to vaccines. Even though vaccine protection is often reduced, the experts emphasize that vaccination remains a key strategy for infection prevention, alongside careful timing around therapy and proactive counseling for patients and their families.

Data presented at the 2026 American Society of Clinical Oncology Annual Meeting add to the “ever-shifting and chaotic space” that is CLL care, says Matthew Lunning, DO. He discusses how new findings are affecting practice with Robert A. Figlin, MD.

During the 31st European Hematology Association (EHA) Congress, June 11–14, 2025, Stockholm, SE, the Lymphoma Hub spoke with Dr. Talha Munir, Leeds Teaching Hospital, Leeds, UK. We asked, What are the most recent findings from the phase I NX-5948-301 trial evaluating bexobrutideg in chronic lymphocytic leukemia (CLL)? This educational resource is independently supported by Nurix. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence Hosted on Acast. See acast.com/privacy for more information.

Evaluate case-based management strategies for chronic lymphocytic leukemia (CLL) from first line to cellular therapy. Credit available for this activity expires: 6/8/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/navigating-next-steps-cll-collaborative-dialogue-2026a1000i1d?ecd=bdc_podcast_libsyn_mscpedu

Payer & Provider Dynamics: Addressing Non-Medical Switching in Oncology for CLL/SLL On this episode guest host Ryan Haumschild, PharmD, MS, MBA, CPEL, Vice President of Pharmacy at Emory University and Emory Health Plan, Winship Cancer Institute, discusses the real-world impact of non-medical switching in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) with Timothy Mok, Manager of Clinical Utilization Intelligence at Kaiser Permanente and board-certified oncology pharmacist, focusing on the drivers behind switching, the risks of disrupting effective therapy, and how shared decision-making and dose modification can help maintain adherence and improve patient outcomes. Sponsored by Abbvie. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

Drs. Wierda and O'Brien discuss new combination treatments for CLL that achieve exceptionally high rates of undetectable disease, especially with triplet regimens. They also show that venetoclax-based retreatment works very well, supporting a move away from chemoimmunotherapy.

Some people with chronic lymphocytic leukemia (CLL) may feel well day to day, but that doesn't mean life stays the same. In this episode, we hear from Annette Holloway, a clinical psychologist living with CLL, as she shares how her diagnosis, treatment decisions, and side effects have shaped her daily life. Also joining us is Elise Curry, RN, OCN, a Clinical Trial Nurse Navigator at Blood Cancer United's Clinical Trial Support Center, who helps break down treatment options, side effects, and the importance of communication with your care team. DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Chronic lymphocytic leukemia (CLL) Clinical Trial Support Center Minimal/measurable residual disease (MRD) Patti Robinson Kaufmann First Connection ® program Online Chat Patient Community Support groups Caregiver support Lessons in Blood Cancer Video: CLL Shared Decision Making in Chronic Leukemias interactive program CLL Society Patient Power Additional Blood Cancer United Support Resources: Information Specialists Financial support Free Nutrition Consultations Free telephone/web patient programs Free booklets Caregiver Workbook Young Adult Resources Survivorship Workbook Advocacy and Public Policy Mental Health Resources Episode supported by AbbVie Inc.; BeOne Medicines; and Genentech, A Member of the Roche Group.The post Chronic Lymphocytic Leukemia (CLL): Managing Treatment and Finding Balance first appeared on The Bloodline with Blood Cancer United Podcast.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/QVU865. CME/CPE/AAPA/IPCE credit will be available until April 25, 2027.B-Keepers: Pharmacist Principles for Effective BTK Targeting in CLL, MCL, and Other B-Cell Cancers In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, BeOne Medicines, and Lilly.Disclosure information is available at the beginning of the video presentation.

Drs. Wierda and O'Brien discuss how fixed-duration venetoclax-based therapy can match continuous BTK inhibitor treatment in CLL while offering deep remissions and time off therapy. They also explore promising real-world CAR T-cell (liso-cel) results and stress the growing importance of vaccination and cancer screening as CLL patients live longer.

Living with a chronic blood cancer can bring uncertainty, questions and a need for support that lasts well beyond diagnosis. In this episode, Nelly shares her experience living with chronic myeloid leukemia (CML), offering an honest look at treatment, side effects and daily life (including raising her three sons.) Joined by hematologist Dr. Lynn Savoie, we explore chronic blood cancers like CML and chronic lymphocytic leukemia (CLL), including how they're diagnoses, treated and managed over time. Visit our website for more information on CLL and CML.Looking for support? Our team is here to help. Contact us today.

In this episode of Treating Together, host Marc Braunstein, MD, PhD, associate professor of medicine at the NYU Perlmutter Cancer Center, sits down with Adam Kittai, MD, associate professor and director of the CLL and Lymphoma programs at NYU Perlmutter Cancer Center, for a deep dive into the rapidly evolving frontline treatment landscape in chronic lymphocytic leukemia (CLL). As chemotherapy continues to give way to targeted and time-limited therapies, clinicians face an increasingly complex array of choices, each influenced by disease biology, patient preferences, and emerging clinical trial data. Key Discussion PointsThe episode focuses on the evolving frontline management of CLL and how clinicians can individualize therapy in an era of expanding options. Highlights include: Patient Evaluation and Diagnosis Considerations: Beyond traditional risk factors such as TP53 mutation and IGHV status, importance is also being placed on patient preference, comorbidities, and treatment goals (eg, time-limited vs continuous therapy) to guide treatment decisions. Therapy Selection and Sequencing Strategy: Dr Kittai offers his view on sequencing decisions in the front line: given the lack of robust comparative data, current evidence supports prioritizing the most appropriate upfront regimen rather than relying on uncertain sequencing strategies across agents. Insights From the AMPLIFY Trial (NCT03836261): With the recent February 2026 FDA approval of acalabrutinib (Calquence) plus venetoclax (Venclexta) in the front line, the discussion highlights progression-free survival (PFS) benefits seen in the AMPLIFY trial and favorable safety of the doublet. The Growing Role of Minimal Residual Disease (MRD): The discussion briefly pivots to the use of MRD testing in the clinic today, including data from trials like GLOW (NCT03462719) and FLAIR (EudraCT: 2013-001944-76), and its potential to guide treatment duration. Emerging Therapeutic Strategies in the Pipeline: The conversation looks to the future of CLL care, including Bruton tyrosine kinase (BTK) degraders, next-generation BCL-2 inhibitors, and novel combinations currently under investigation. Managing Richter's Transformation: Dr Kittai covers evolving combination approaches for this aggressive cancer that aim to target both CLL and lymphoma biology, moving beyond chemoimmunotherapy.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most intriguing advancements and strategic moves shaping the future of drug development and patient care. Regeneron has recently ventured into the radiopharmaceuticals market through a substantial $2.1 billion agreement with Australia's Telix Pharmaceuticals. This move marks a significant diversification from Regeneron's traditional focus, such as obesity treatments, to an area that combines radioactive isotopes with targeting molecules for diagnosing and treating diseases like cancer more effectively. The strategic alliance positions Regeneron as a formidable player in this emerging field, promising to expand its therapeutic portfolio and revenue streams. In oncology innovation, GSK is pushing forward with a bold initiative, conducting Phase 3 trials for antibody-drug conjugates (ADCs) in collaboration with Hansoh Pharmaceutical. This effort underscores GSK's commitment to expanding its oncology pipeline, particularly in targeting unmet medical needs through innovative therapies. Antibody-drug conjugates are designed to deliver cytotoxic agents directly to cancer cells, minimizing damage to healthy tissues and offering a precision approach to cancer treatment. Allogeneic CAR-T therapies are also making waves, with Allogene Therapeutics reporting promising early data from their off-the-shelf CAR-T therapy, cema-cel. This therapy effectively eradicated minimal residual disease in lymphoma patients, highlighting the potential of allogeneic approaches to provide accessible cancer treatments without the logistical complexities of autologous methods. In another significant milestone, Ideaya Biosciences, in collaboration with Servier, achieved success with their eye cancer drug candidate meeting its primary endpoint in a crucial Phase 2/3 trial. This success sets the stage for an accelerated FDA approval filing, offering new hope for patients dealing with this challenging condition. Revolution Medicines has made notable progress in oncology as well, with its highly anticipated RAS inhibitor demonstrating improved survival outcomes in a Phase 3 trial for pancreatic cancer. Extending survival by an average of six months compared to chemotherapy could redefine treatment paradigms for one of the most aggressive cancer types. Not every development has been favorable, however. Replimune faced its second FDA rejection for its melanoma candidate RP1, leading to workforce reductions—a testament to the rigorous nature of regulatory approvals and the challenges companies face when bringing novel therapies to market. Meanwhile, BioNTech and Synox Therapeutics are advancing towards FDA approval for their tumor-targeting therapies. These efforts could intensify competition within the oncology space, challenging established giants like AstraZeneca and Daiichi Sankyo. In pain management, AbbVie has expanded its portfolio through a $745 million deal with Haisco Pharmaceutical Group for two non-opioid pain treatment candidates. This move aligns with growing demand for non-opioid alternatives amid the opioid crisis, reflecting a strategic shift towards safer pain management solutions. Spyre Therapeutics has also reported positive Phase 2 results for its ulcerative colitis drug, setting it up as a potential competitor against Takeda's Entyvio. Success here could enhance therapeutic options for patients struggling with this chronic condition, highlighting continued innovation in gastrointestinal disorders. Eli Lilly's recent success with its BTK inhibitor Jaypirca marks a pivotal moment in chronic lymphocytic leukemia (CLL) treatment strategies. Having demonstrated substantial efficacy in a Phase 3 clinical trial—the fourth positive readout—Jaypirca establishes itself as an industry first. Its fixed-duratioSupport the show

Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer. As a glucoCORticoid receptor antagonist, it is hard to pronounce. Also, a 10-year follow-up study of ibrutinib provides big picture insight on the impact of the BTKi era in CLL. Link: https://doi.org/10.1182/blood.2025029971 Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

On this episode Kirollos Hanna, PharmD, Director of Pharmacy at Minnesota Oncology, discusses the rapidly shifting treatment landscape for chronic lymphocytic leukemia (CLL). The discussion covers the transition toward oral fixed-duration frontline regimens, the latest 2026 NCCN guidelines, and the emerging role of MRD testing. They also explore the clinical and economic implications of these therapies, including how the Inflation Reduction Act (IRA) is reshaping Medicare formulary strategies and patient access. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

In today's episode Mazyar Shadman, MD, MPH, discussed results from a post hoc indirect comparison that evaluated zanubrutinib (Brukinsa) from phase 3 SEQUOIA trial (NCT03336333) compared with acalabrutinib (Calquence) plus venetoclax (Venclexta) from the phase 3 AMPLIFY trial (NCT03836261) in patients with treatment-naive chronic lymphocytic leukemia (CLL). Dr Shadman is a professor in the Clinical Research Division, medical director of Cellular Immunotherapy, and the Innovators Network Endowed Chair at Fred Hutchinson Cancer Center in Seattle, Washington.In our exclusive interview, Dr Shadman began with a top-line overview of how the indirect comparison was conducted and the rationale behind it. After discussing the design of the comparison, Dr Shadman then dove into a conversation on the results of the study, in addition to how it will help oncologists and patients alike in the clinic. Finally, Dr Shadman looked to the future of CLL management and underscored what research he would like to see conducted following the comparison and its results.

Drs. O'Brien and Wierda discuss how fixed-duration venetoclax-based therapy can match continuous BTK inhibitor treatment in CLL while offering deep remissions and time off therapy. They also explore promising real-world CAR T-cell (liso-cel) results and stress the growing importance of vaccination and cancer screening as CLL patients live longer.

Meghan Gutierrez, CEO of the Lymphoma Research Foundation, and Jennifer Branstetter, the Executive Director, North America Corporate Affairs at BeOne Medicines, join me to discuss the growing use of AI in patient care with a specific focus on individuals with lymphoma and other blood cancers. Emphasis is on the necessity of a collaborative, patient-centric approach to developing AI tools, bringing together patient advocacy organizations, healthcare professionals, and pharma partners to provide accurate information to patients. The goal is to serve a diverse population by providing personalized, accessible information to help patients have more meaningful discussions with their healthcare providers, not to replace the clinician's role. Jen explains, "We know that tens of millions of people are using AI tools in general, like ChatGPT, for health questions, including patients with blood cancers like chronic lymphocytic leukemia or CLL, they're all turning to the different AI tools that are out there. And from our perspective, we see this continuous growth of use, we want to make sure that the right healthcare information is getting fed into those AI resources and tools so that patients are getting the most accurate information possible."   Meg elaborates, "Many patients are using these AI tools to make sense of everything from their PET scans to their blood results, to some of the treatment language they receive in their clinician's or doctor's office. And one of the things that I heard recently from a cancer patient who had uploaded his scans and some test results into an AI platform. And he called me incredibly concerned. He was very concerned about his prognosis and the limited treatment options that he believed were available to him." "So when I pressed further, I found out that this AI platform was the only source of information that he had. So I became concerned when I recognized that the information he received was antiquated. So the treatment results and some of the information he was working from in this incredibly anxious and anxiety-provoking moment were 10 years old. And so in this case, antiquated information was as dangerous as inaccurate information. And both of these remain top concerns at the Lymphoma Research Foundation. And I think across our sector, as we see more and more patients using these tools and platforms to help educate them about their disease and their treatment options." #LymphomaResearchFoundation #LRF #BeOneMedicines #LymphomaAwareness #AIinHealthcare #PatientAdvocacy #BloodCancer #HealthcareInnovation #PatientEmpowerment #PrecisionMedicine #CLL #HealthTech #CancerCare lymphoma.org BeOneMedicines.com Download the transcript here

Meghan Gutierrez, CEO of the Lymphoma Research Foundation, and Jennifer Branstetter, the Executive Director, North America Corporate Affairs at BeOne Medicines, join me to discuss the growing use of AI in patient care with a specific focus on individuals with lymphoma and other blood cancers. Emphasis is on the necessity of a collaborative, patient-centric approach to developing AI tools, bringing together patient advocacy organizations, healthcare professionals, and pharma partners to provide accurate information to patients. The goal is to serve a diverse population by providing personalized, accessible information to help patients have more meaningful discussions with their healthcare providers, not to replace the clinician's role. Jen explains, "We know that tens of millions of people are using AI tools in general, like ChatGPT, for health questions, including patients with blood cancers like chronic lymphocytic leukemia or CLL, they're all turning to the different AI tools that are out there. And from our perspective, we see this continuous growth of use, we want to make sure that the right healthcare information is getting fed into those AI resources and tools so that patients are getting the most accurate information possible."   Meg elaborates, "Many patients are using these AI tools to make sense of everything from their PET scans to their blood results, to some of the treatment language they receive in their clinician's or doctor's office. And one of the things that I heard recently from a cancer patient who had uploaded his scans and some test results into an AI platform. And he called me incredibly concerned. He was very concerned about his prognosis and the limited treatment options that he believed were available to him." "So when I pressed further, I found out that this AI platform was the only source of information that he had. So I became concerned when I recognized that the information he received was antiquated. So the treatment results and some of the information he was working from in this incredibly anxious and anxiety-provoking moment were 10 years old. And so in this case, antiquated information was as dangerous as inaccurate information. And both of these remain top concerns at the Lymphoma Research Foundation. And I think across our sector, as we see more and more patients using these tools and platforms to help educate them about their disease and their treatment options." #LymphomaResearchFoundation #LRF #BeOneMedicines #LymphomaAwareness #AIinHealthcare #PatientAdvocacy #BloodCancer #HealthcareInnovation #PatientEmpowerment #PrecisionMedicine #CLL #HealthTech #CancerCare lymphoma.org BeOneMedicines.com Listen to the podcast here

Helen talsk to Dr Renata Walewska about CLL management

During a visit to Columbia University Irving Cancer Research Center, experts across hematologic oncology shared their perspectives on key trends and developments in their respective fields. These conversations explored novel therapeutic approaches and translational research that may advance the paradigm across different leukemia, multiple myeloma, and lymphoma populations.First, Nicole Lamanna, MD, an associate clinical professor of medicine in the Hematologic Malignancies Section of the Hematology/Oncology Division at Irving Medical Center, discussed relevant advancements in the management of chronic lymphocytic leukemia (CLL). She described how the FDA approval of fixed-duration acalabrutinib (Calquence) plus venetoclax (Venclexta) may affirm a shift away from standard chemoimmunotherapy in the field. Her discussion also emphasized evaluating the adverse effects and benefit/risk profiles of drug classes such as BTK inhibitors and BCL-2 inhibitors during the treatment decision-making process.Next, Rajshekhar Chakraborty, MD, an assistant professor of medicine in the Division of Hematology/Oncology at Irving Medical Center, touched upon critical themes related to the use of bispecific antibodies for patients with multiple myeloma and other plasma cell disorders. Educating providers on the utility of bispecific antibodies in earlier treatment settings, he noted, is one of the important challenges that the field must address to expand usage of these therapies in community practices. He also highlighted findings from the phase 3 MajesTEC-3 trial (NCT05083169) and how they support the clinical utility of teclistamab-cqyv (Tecvayli) plus daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients with relapsed/refractory disease.Finally, Hua-Jay “Jeff” Cherng, MD, an assistant professor of medicine in the Lymphoma Program in the Division of Hematology and Oncology at Irving Medical Center, detailed translational work that may shape clinical practice in the lymphoma space. He spoke about research aiming to move markers like ctDNA and minimal residual disease from “the bench to the bedside” as part of clinical decision-making for patients with diffuse large B-cell lymphoma (DLBCL). Other future focuses, Cherng said, include leveraging molecular genotyping to improve outcomes for higher-risk subgroups or even replacing chemotherapy with less toxic targeted agents.References CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting. News release. AstraZeneca. February 20, 2026. Accessed March 11, 2026. https://tinyurl.com/38zbx96s Mateos MV, Bahlis N, Perrot A, et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator's choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (pts) with relapsed refractory multiple myeloma (RRMM): results of MajesTEC-3. Blood. 2025;146(suppl 2):LBA-6. doi:10.1182/blood-2025-LBA-6

Featuring an interview with Prof Constantine Tam, including the following topics: Evolving first-line treatment paradigm for patients with previously untreated chronic lymphocytic leukemia (CLL) (0:00) Considerations for the administration of first-line venetoclax-based regimens (3:24) Mechanism of action of sonrotoclax and observed early-phase efficacy in combination with zanubrutinib; minimal residual disease as a potential clinical trial endpoint (10:01) Continuous versus fixed-duration first-line treatment approaches for previously untreated CLL (14:38) Selecting between up-front acalabrutinib- and zanubrutinib-based time-limited therapy options (19:07) Up-front treatment selection for patients with del(17p) CLL (24:01) Stopping and restarting acalabrutinib for frail patients with previously untreated CLL (26:43) Pirtobrutinib for treatment-naïve and relapsed/refractory CLL/small lymphocytic lymphoma: Results from the Phase III BRUIN CLL-314 and BRUIN CLL-313 trials (30:20) Lisocabtagene maraleucel as treatment for patients with double-refractory CLL (37:00) Perspectives on future roles of novel therapies and treatment strategies (43:11) CME information and select publications

In this episode, Matthew S. Davids, MD, MMSc; Nelson Hamerschlak, MD, PhD; and Stephen Stilgenbauer, MD, discuss how recently presented data from ASH 2025 are shaping real-world treatment decisions for patients with relapsed/refractory chronic lymphocytic leukemia, including: How covalent and noncovalent BTK inhibitors are currently used in the United States, Brazil, and Europe Practical sequencing decisions after disease progression Emerging BTK degradersas a promising option for heavily pretreated patients Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Matthew S. Davids, MD, MMSc Associate Professor of Medicine Harvard Medical School Leader, Lymphoma Program Dana-Farber/Harvard Cancer Center Director of Clinical Research, Division of Lymphoma Dana-Farber Cancer Institute Boston, Massachusetts Nelson Hamerschlak, MD, PhD Head of the Department of Hematology, BMT and Clinical Cell Therapy Einstein Hospital Israelita Sao Paulo, Brazil Stephen Stilgenbauer, MD Medical Director, Comprehensive Cancer Center Ulm (CCCU) Head, Early Clinical Trials Unit (ECTU) Head, Division of CLL Department of Internal Medicine III Comprehensive Cancer Center Ulm (CCCU) University of Medical Center Ulm Ulm, Germany Link to the full program: https://bit.ly/4rsZlqF Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Featuring a slide presentation and related discussion from Prof Constantine Tam, including the following topics: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL): Results from the randomized CLL17 trial (0:00) Six-year follow-up data from the Phase III SEQUOIA trial of zanubrutinib for patients with treatment-naïve CLL and those with del(17p) CLL not randomly assigned (4:59) Primary endpoint analysis of the randomized STAIR trial of time-limited acalabrutinib monotherapy for frail patients with previously untreated CLL (7:25) Safety analyses of acalabrutinib/venetoclax (AV) or AV in combination with obinutuzumab for previously untreated CLL (10:50) Three-year results with zanubrutinib combined with venetoclax in arm D of the Phase III SEQUOIA trial for treatment-naïve CLL (17:15) Early-phase data with sonrotoclax combinations as front-line treatment of CLL (19:12) Pirtobrutinib for treatment-naïve and relapsed/refractory CLL/small lymphocytic lymphoma: Results from the Phase III BRUIN CLL-314 and BRUIN CLL-313 trials (23:27) Long-term extension (LTE1) results from the Phase III ALPINE trial of zanubrutinib versus ibrutinib in patients with relapsed/refractory CLL or small lymphocytic lymphoma (R/R CLL/SLL) (28:53) Updated efficacy and safety results of the Bruton tyrosine kinase degrader BGB-16673 in patients with R/R CLL/SLL from the ongoing phase 1 CaDAnCe-101 study (30:35) Real-world outcomes of lisocabtagene maraleucel in CLL (33:04) CME information and select publications

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-first-line-therapy-for-cll/39262/ This activity focuses on optimizing first-line treatment strategies for patients with chronic lymphocytic leukemia (CLL). Drs. William Wierda and Matthew Davids discuss key distinctions between continuous BTK inhibitor therapy and time-limited venetoclax-based regimens, while highlighting considerations such as comorbidities, toxicities, IGHV status, and TP53 aberrations. They examine recent and emerging data from trials including CLL17, AMPLIFY, and BRUIN CLL-313, as well as novel agents. The conversation underscores the importance of personalized therapy selection in frontline CLL care.=

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/double-class-refractory-cll-in-community-practice-current-and-future-management/39261/ Dr. John Byrd discusses current and emerging strategies for managing double-class-refractory chronic lymphocytic leukemia (CLL) in community settings. He emphasizes the importance of distinguishing resistance from intolerance to BTK inhibitors through clinical history and molecular testing. Data from the BRUIN trial support the use of pirtobrutinib in select patients, while newer agents, including BTK degraders and bispecific antibodies, offer promising potential. Collaboration with CLL specialists is encouraged to guide therapy sequencing and access advanced treatments such as CAR T-cell therapy.=

CME credits: 0.25 Valid until: 30-01-2027 Claim your CME credit at https://reachmd.com/programs/cme/navigating-treatment-sequencing-after-frontline-treatment-failure-in-cll/39260/ This activity explores treatment sequencing strategies for chronic lymphocytic leukemia (CLL) following frontline therapy failure based on prior therapies, mechanisms of resistance, and minimal residual disease status. Dr. Jennifer Brown discusses how distinguishing between resistance and intolerance to BTK and BCL2 inhibitors informs second-line treatment decisions. The conversation highlights the role of measurable residual disease (MRD) in guiding therapy duration, biomarker reassessment, and shared decision-making based on patient preferences and clinical risk factors.=

In deze podcast, mede mogelijk gemaakt door AstraZeneca en BeOne Medicines, spreekt wetenschapsjournalist Judith Cohen met prof. dr. Stephan Stilgenbauer (Universiteit Ulm, Duitsland) over de huidige eerstelijnsbehandelopties voor patiënten met CLL. Aan bod komen de belangrijkste punten van de meest recente richtlijnupdates en zijn ervaring met de behandeling van CLL-patiënten.Disclosures Prof. dr. Stephan Stilgenbauer: AbbVie, Amgen, AstraZeneca, BeOne Medicines, BMS, Galapagos, Gilead, GSK, Hoffmann-La Roche, Johnson&Johnson, Lilly, Novartis, Sunesis.

In de podcastserie Proefschriften spreekt aios interne geneeskunde dr. Tessa Steenbruggen met promovendi. In deze speciale aflevering spreekt zij met dr. Paul Hengeveld over zijn proefschrift, getiteld: ‘Molecular risk stratification in chronic lymphocytic leukemia'. Paul vertelt hoe moleculaire risicostratificatie kan helpen in voorspellen van de prognose van patiënten met chronische lymfatische leukemie (CLL) en filosofeert over de toekomst van MRD (measurable residual disease) bij CLL. Paul heeft 27 maart 2024 zijn proefschrift succesvol verdedigd aan de Erasmus Universiteit bij prof. dr. Ton Langerak en co-promotoren dr. Mark-David Levin en dr. Peter Westerweel. Hij kreeg dit jaar tijdens de hematologiedagen het Jaap Steenbergen Stipendium voor het beste hematologieproefschrift van 2024.Referenties Inspiratietip: Belgische televisieserie - Met gevoel voor tumor Prognose CLL – THEMIS2 MRD CLL10 Sequentiële MRD HOVON-139 FLAIR-studie

CLL #1426 (feat. Christian DuGuay) 03/18/2001 – Sunday Night Show Source – Lost Tape (2020) with Debbi and Unknown Stream Recording (2001) Patches This episode is now remastered and 100% complete. Huge Audio Upgrade. Aries Spears “No Shows” and Christian proves to be very subdued, Dr. Drew is broadcasting remotely from Seattle. From Wiki: Christian Duguay (born January 3, 1970) is an American actor and comedian. Duguay is most notable as one of the recurring cast of sketch comedy series MADtv. The Love Between The Two Hosts – CLL on Youtube, with Video for select episodes. Music Provided by Rich Banks Check out His Website and Soundcloud to hear more of his awesome work and perhaps commission him for your next project. Read More →

CLL #1425 (feat. Sasha Alexander) 03/15/2001 – Thursday Night Show Source – Lost Tape (2020) with Debbi and Chris Tape (2020) and Unknown Stream Recording (2001) Patches This episode is now remastered and 100% complete. Huge audio upgrade, Sasha is making her only known CLL appearance and proves to be a delight. Her appreciation of Adam’s humor takes the comedy to another level, solid guest! From Wiki: Suzana Drobnjaković[2] (born May 17, 1973),[3][4] known by her stage name Sasha Alexander, is an American actress. She played Gretchen Witter on Dawson’s Creek and has acted in films including Yes Man (2008) and He’s Just Not That Into You (2009). Alexander played Caitlin Todd for the first two Read More →

CLL #1423 (feat. Nelly Furtado) 03/13/2001 – Tuesday Night Show Source – Debbi and Chris Tape (2020) with Unknown Stream Recording (2001) Patches This episode is now remastered and 100% complete. The missing 13 minutes have been restored. Nelly Furtado is making her first of two visits during the Adam Carolla era, she returned to the show in 2004 to promote her follow up album ‘Folklore.’ Nelly proves to be a very fun guest and even made best of for this very appearance. Adam and Drew seem to love her, sleeper classic guest! From Wiki: Nelly Kim Furtado ComIH (/fɜːrˈtɑːdoʊ/, Portuguese: [fuɾˈtaðu]; born December 2, 1978) is a Portuguese-Canadian singer and songwriter. Furtado first gained fame with her debut album, 

CLL #1424 (feat. Nick Carter) 03/14/2001 – Wednesday Night Show Source – Debbi and Chris Tape (2020) with Unknown Stream Recording (2001) Patches This episode is now remastered and 100% complete. The audio quality is moderately improved. Nick brought McDonald’s that he can be heard smacking on to many listener’s chagrin, this is Nick’s only appearance on CLL, Enjoy it! From Wiki: Nickolas Gene Carter (born January 28, 1980)[1] is an American musician, singer and actor. He is best known as a member of the pop group the Backstreet Boys. As of 2015, Carter has released three solo albums, Now or Never, I’m Taking Off and All American during breaks between Backstreet Boys schedules, Read More →

CLL #1421 (feat. The Love Between The Two Hosts) 03/11/2001 – Sunday Night Show Source – Debbi and Chris Tape (2020) with Stream Recording (2001) Patches This episode is now remastered and 100% complete. Adam and Drew announce a new plan to follow up with interesting callers. The Love Between The Two Hosts – CLL on Youtube, with Video for select episodes. Music Provided by Rich Banks Check out His Website and Soundcloud to hear more of his awesome work and perhaps commission him for your next project. Venmo

CLL #1422 (feat. The Love Between The Two Hosts) 03/12/2001 – Monday Night Show Source – Lost Tape (2020) with Stream Recording (2001) Patches This episode is now remastered and 100% complete. Adam has a bit of a gas night and Drew gets farted out of the studio. The Love Between The Two Hosts – CLL on Youtube, with Video for select episodes. Music Provided by Rich Banks Check out His Website and Soundcloud to hear more of his awesome work and perhaps commission him for your next project. Venmo

CLL #1420 (feat. The Love Between The Two Hosts) 03/08/2001 – Thursday Night Show Source – Stream Recording (2001)  This episode is now remastered and still 100% complete. Adam announces the return of the drops next week and they institute a new policy going forward regarding bogus calls.  The Love Between The Two Hosts – CLL on Youtube, with Video for select episodes. Music Provided by Rich Banks Check out His Website and Soundcloud to hear more of his awesome work and perhaps commission him for your next project. Venmo